News
JAZZ
103.33
-2.14%
-2.26
Jazz Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Equal-Weight on Jazz Pharmaceuticals, Lowers Price Target to $150
Benzinga · 3d ago
Jazz Pharmaceuticals (JAZZ) Receives a Hold from Morgan Stanley
TipRanks · 3d ago
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
NASDAQ · 3d ago
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Federal legalization of cannabis could lead to increased pharmaceutical investment and further consolidation in the cannabis industry. The cannabis industry is already experiencing consolidation. The rescheduling of cannabis to Schedule III is expected to open new avenues for medical research and investment. The FTC recently highlighted the influence of pharmacy benefit managers on drug prices due to market consolidation.
Benzinga · 4d ago
Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country
Avicanna Inc. Has completed the commercial export of its products into Singapore. In Singapore, cannabis remains stigmatized and illegal. The Central Narcotics Bureau of Singapore is of the stance that cannabis should be considered an illicit drug. Avicanna's products are now available in 18 international markets.
Benzinga · 4d ago
Is The Options Market Predicting A Spike In JAZZ Pharmaceuticals (JAZZ) Stock?
NASDAQ · 4d ago
Zymeworks: A Somewhat Complicated Story
Zymeworks Inc. Is a Vancouver-based oncology-focused clinical-stage biopharma firm. The company's lead candidate, zanidatamab, could have its first FDA approval in hand before the end of 2024. Zymeworks has significant partnership deals with Jazz Pharmaceuticals and BeiGene, Ltd. We update our analysis of the company in a follow-up article.
Seeking Alpha · 6d ago
JAZZ PHARMACEUTICALS PROMOTES SAMANTHA PEARCE TO CHIEF COMMERCIAL OFFICER
Reuters · 6d ago
Weekly Report: what happened at JAZZ last week (0701-0705)?
Weekly Report · 07/08 09:03
Jazz Pharmaceuticals Is Maintained at Neutral by UBS
Dow Jones · 07/02 19:02
Jazz Pharmaceuticals Price Target Cut to $113.00/Share From $117.00 by UBS
Dow Jones · 07/02 19:02
Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Seven analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ) in the last three months. The company has an average 12-month price target of $184.86. Jazz is an Ireland-domiciled biopharmaceutical firm focused on treatments for sleeping disorders and oncology. The firm's revenue growth rate is lower than its industry peers.
Benzinga · 07/02 19:00
UBS Maintains Neutral on Jazz Pharmaceuticals, Lowers Price Target to $113
Benzinga · 07/02 18:52
Weekly Report: what happened at JAZZ last week (0624-0628)?
Weekly Report · 07/01 09:03
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
NASDAQ · 06/27 17:28
Weekly Report: what happened at JAZZ last week (0617-0621)?
Weekly Report · 06/24 09:03
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has US$5.71b of debt on its balance sheet. The company's debt is 2.8 times its earnings, but is not a concern for shareholders. Debt can be a good tool for businesses to use to shore up their balance sheets. Jazz Pharmaceuticals's EBIT fell 16% in the last year, but the company has more free cash flow than debt. We've identified 3 warning signs with the company but don't think its debt is a problem.
Simply Wall St · 06/23 13:49
Baird sees Jazz study failure as positive for rival Praxis
Seeking Alpha · 06/21 18:41
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Seeking Alpha · 06/21 13:15
More
Webull provides a variety of real-time JAZZ stock news. You can receive the latest news about Jazz Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About JAZZ
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).